Nasdaq
$1.40▲ 1.08%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $150.0MShares out 1.100M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
5- 10.15Pre-market26.10.15 22:00SCHEDULE 13DOwnership#●●●
MAXCYTE, INC.
Liontrust Investment Partners LLP has filed a Schedule 13D regarding its acquisition of shares in MaxCyte, Inc. This filing indicates a change in the company's ownership structure and signals the investor's potential for exercising voting rights or future involvement in corporate governance.…more
$1.40+1.08%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.14Pre-market26.10.14 21:108-KKey event
MAXCYTE, INC.
MaxCyte announced preliminary third-quarter 2026 revenue and raised its full-year 2026 revenue guidance to approximately $34 million, up from the previous range of $30 million to $32 million. The company reported core business revenue of approximately $8.1 million for the third quarter, representing a 26% increase year-over-year, alongside over $1.0 million in SPL program-related revenue.…more
$1.40+1.08%vs prev closeView filingShare - 8.12After-hours26.08.13 05:148-KKey event
MAXCYTE, INC.
MaxCyte reported $7.3 million in revenue for the second quarter of 2026, a 15% decrease year-over-year, while announcing a new multi-platform technology license partnership with Genentech. The company's net loss improved to $8.9 million from $12.4 million in the same period last year, and it reiterated its full-year 2026 revenue guidance of $30 million to $32 million.…more
$1.40+1.08%vs prev closeView filingShare
4 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.15Pre-market26.10.15 22:07#●●●
Liontrust Investment Reports 5% Stake in MaxCyte
Liontrust Investment Partners disclosed a 5% stake in MaxCyte as of October 14. This filing indicates a significant position taken by an institutional investor in the company.…more
$1.40+1.08%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 10.14Pre-market26.10.14 21:05
●●●●●●●● ●●●●● ●●●●●●
MaxCyte has raised its full-year 2026 revenue guidance following strong third-quarter performance and milestone achievements from its strategic partnerships. The company reported double-digit growth in its core business and increased expectations for its platform licensing program.…more
$1.40+1.08%vs prev close - 9.23Pre-market26.09.23 21:05
●●●●●●●● ●●●●● ●●●●●●
MaxCyte has appointed Sidharth Kapileshwar, formerly of Danaher, as its new Chief Corporate Development Officer. This leadership hire is intended to drive the company's strategic growth and business expansion initiatives.…more
$1.40+1.08%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report